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Background. The purpose of this study was to examine the re-
lationship between glomerular filtration rate (GFR) measured
at 5 years’ diabetes duration and annual urine albumin excre-
tion in a prospective cohort of children with type 1 diabetes
(T1DM).
Methods. Three hundred and eight children were followed
from diagnosis of T1DM [aged 9.8 years (range 0.4–15.9) for
a median duration of 10.9 years (6.0–17.8) with annual assess-
ments comprising measurement of HbA1c and 3 urine samples
for albumin:creatinine ratio (ACR). GFR was measured in all
children at 5 years’ diabetes duration.
Results. Two hundred forty-three (78.8%) subjects were nor-
moalbuminuric (MA−) for the duration of the study. At 5
years: 35 (11.4%) subjects had MA (MA+) and 30 (9.7%) sub-
jects were normoalbuminuric but developed MA during sub-
sequent follow-up annual assessments (future MA+). In the
future MA+ group compared to the MA+ and MA− groups;
GFR was higher (167 vs. 134 vs. 139 mL/min/1.73m2, P < 0.002);
the prevalence of hyperfiltration (GFR >125 mL/min/1.73m2)
was greater (97 vs. 57 vs. 64%, P = 0.006) and HbA1c levels
were higher (11.4 vs. 10.8 vs. 9.7%, P < 0.001). The probability
(Cox Model) of having hyperfiltration at 5 years’ duration was
related to puberty (a 1.7-fold increased risk with puberty on-
set) and poor glycemic control (a 10% increased risk for a 1%
increase in HbA1c). Comparing subjects with and without hy-
perfiltration, prior to the first GFR measurement no difference
in ACR levels existed; however, after this time median ACR
levels were significantly greater [1.2 (0.1–86.4) vs. 0.9 (0.1–71.6)
mg/mmol, P =0.003], independent of age and HbA1c levels. The
probability of developing MA between 5 and 10 years’ duration
was associated with poor glycemic control (a 30% increased risk
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for a 1% increase in HbA1c) and higher GFR at 5 years (22%
increased risk for a 10 mL/min/1.73m2 rise in GFR).
Conclusion. Glomerular hyperfiltration is associated with
puberty and increasing ACR levels and is predictive of MA
independent of HbA1c. This suggests that factors other than
poor glycemic control may be involved in the pathogenesis of
early diabetic nephropathy and early intervention with medical
therapy to reduce GFR may be beneficial even before onset of
MA.
Early landmark experimental studies of renal disease
by Brenner et al implicated glomerular hypertension and
hyperfiltration in mediating progressive renal damage [1,
2]. Maladaptive hemodynamic changes in response to a
functional decrease in nephron number were shown to
increase glomerular capillary pressure and elevate single
nephron glomerular filtration rate (GFR). In these non-
diabetic models, glomerulosclerosis and proteinuria were
the eventual outcome. Subsequent data suggested that
systemic hypertension was not a requirement for renal in-
jury, emphasizing the importance of glomerular hemody-
namic change and, in particular, angiotensin-dependent,
glomerular hypertension [3–5]. Human models of renal
injury are in keeping with these experimental data. Pa-
tients with unilateral renal agenesis [6], congenitally re-
duced nephron number [7], and acquired reduction in
renal mass [8] hyperfiltrate from birth and may develop
proteinuria in association with glomerular sclerosis.
It is suggested that this model of renal injury may ap-
ply to the early diabetic kidney. Adult Munich-Wistar
diabetic rats hyperfiltrate and have evidence of raised in-
traglomerular pressure [9], alleviation of which prevents
the development of glomerulosclerosis [10]. In humans,
long-standing type 1 diabetes mellitus (T1DM) is char-
acterized by a decline in GFR compared to the general
population; however, in the early stages of T1DM hy-
perfiltration and increased renal size are characteristic
[11, 12], and studies have shown that hyperfiltration may
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predict development of nephropathy [13, 14]. These
findings may reflect poor glycemic control as hyperfil-
tration correlates with HbA1c levels in subjects of short
diabetes duration [15]. However, the association between
hyperfiltration and nephropathy risk was subsequently
found to be independent of metabolic control [16, 17].
Other data are conflicting and have found no such as-
sociation, but one study was retrospective and included
data prior to insulin therapy [18], and in another, subjects
were older and had long diabetes duration [19]. All stud-
ies to date are clinic based, have small sample size, and
involve a heterogeneous group of patients. Thus, it is pos-
sible that results may be confounded by factors such as
age, diabetes duration, and later intervention therapy. In
addition, as microalbuminuria may regress in up to 50%
of subjects at the end of puberty [20], further bias may be
introduced if subjects are not followed from diagnosis of
diabetes or for sufficient time.
Thus, there remains a need for a large study detailing
changes in longitudinal urine albumin excretion and de-
velopment of microalbuminuria (MA) in relation to GFR
levels and other putative risk factors. We report results
of measurements of annual urine albumin:creatinine ra-
tio (ACR) and predictor variables, in a large cohort of
children diagnosed with T1DM and followed prospec-
tively through puberty into young adulthood, in rela-
tion to GFR measurements made at 5 years’ diabetes
duration.
STUDY DESIGN
The Oxford Regional Prospective Study (ORPS)
The Oxford Regional Prospective Study (ORPS) was
established in 1986, and the characteristics of the cohort
have previously been described [21]. Children <16 years
of age in the defined geographic region of Oxford Health
Authority were recruited between 1986 and 1997 within
3 months of diagnosis of diabetes of T1DM to receive an-
nual assessments. Case ascertainment was >95%, with
479 subjects recruited into the study by 1997. Ethical
approval was obtained from the district ethics commit-
tees in the region, with written consent from the parents.
Children were asked to assent before entering the study.
To date, median duration of follow-up is 10.9 years (6.0–
17.8).
Annual assessments
Subjects were assessed annually from the end of the
first year from diagnosis. Assessments consisted of mea-
surements of height, weight, blood pressure, and 3 con-
secutive early morning (first void) urine specimens for the
measurement of ACR. Blood samples were collected for
the centralized measurement of HbA1c. Subjects at each
assessment reported prescribed daily insulin dose and
prevalence of smoking. A subcohort of subjects within
the region of Oxford (N = 42) also had renal ultrasound
measurements, made by the same observer. In addition
to the usual assessment, in a subcohort of subjects, a GFR
measurement was undertaken at 5 years’ diabetes dura-
tion (N = 308), and in some subjects was repeated at 10
years (N = 102).
Definition of MA and puberty
Microalbuminuria was defined as an ACR >3.5
mg/mmol in males and >4.0 mg/mmol in females and <35
mg/mmol in 2 out of 3 consecutive early morning urine
collections. This corresponded to an albumin excretion
rate of between 20 and 200 mcg/minute [21]. Persistent
MA was defined as the presence of MA for at least 2
consecutive years, and transient MA was defined as the
presence of MA for a single year with subsequent regres-
sion to normal. Because Tanner staging was unavailable,
age 11 years was used as a surrogate marker for the onset
of puberty.
Subjects
A total of 410 GFR measurements were made over
a median duration of follow-up of 6.8 years (range 1.0–
11.1). GFRs were undertaken in 308 subjects at 5 years’
diabetes duration (Fig. 1). Of these 308 subjects, those
who were normoalbuminuric for the whole duration of
follow-up were designated MA− subjects (N = 243,
78.8%). Subjects who were normoalbuminuric at 5 years
but went on to develop MA during subsequent follow-up
were designated future MA+ subjects (N = 30, 9.7%).
Subjects with MA at 5 years or during previous annual
assessments were designated MA+ subjects (N = 35,
11.4%). Of 308 subjects 102 had a further second GFR
measurement at around 10 years’ diabetes duration.
METHODS
Height was measured on wall-mounted stadiometers
and weight measured on electronic scales. Until 1994, for
measurement of albumin, urine samples were stored at
−20◦C. After this time, urine was stored at−70◦C because
of reports of the detrimental effects of storage at −20◦C.
Albumin was measured centrally by a double antibody
enzyme-linked immunosorbent assay (ELISA) method
described previously [21]. The within and in-between as-
say coefficient of variation (CV) was 6% and 12%, respec-
tively. Creatinine was measured using a modified Jaffe
method (Unimate 7; Roche Diagnostic Systems, Basel,
Switzerland) on a Cobas Mira (Roche Diagnostic Sys-
tems) automated spectrophotometer. The CV was 2%
at 2.2 mmol/L. Glycated hemoglobin was measured cen-
trally, initially by an electrophoretic method (Ciba Corn-
ing Diagnostics, Halstead, UK), which was replaced by
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Median diabetes duration
5.1 years (3.2-6.9)
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Median diabetes duration
9.2 years (4.0-11.1)
N = 102
Fig. 1. Schematic representation of subjects
receiving 1 (at 5 years) and 2 (at 10 years) GFR
measurements and their albuminuric status.
Of the 308 subjects who had GFR measured,
those who were normoalbuminuric for the
whole duration of follow-up were designated
MA− subjects (N= 243). Subjects who were
normoalbuminuric at the time of the first GFR
but went on to develop MA during subse-
quent annual assessments were designated fu-
ture MA+ subjects (N= 30). Subjects with
MA at the time of the first GFR measurement
were designated MA+ subjects (N= 35).
high-performance liquid chromatography (HPLC - DIA-
MAT; Bio-Rad, Hemel Hempstead, UK) in 1992 [22]. The
relationship between the 2 methods was carefully evalu-
ated and has been described previously [21]. The within-
batch CV for the HPLC method was 2.2% and 1.3% at a
level of 9.8% and 10.1%, respectively. The between-batch
CV was 3.5% and 2.2% at 5.6% and 10.1%, respectively.
Renal size was measured using the real-time Acuson
128 ultrasound machine (Acuson, Mountain View, CA,
USA) by the same observer, while children (all normally
hydrated) lay in the prone position. The renal axis di-
verges caudally from the main midline body plane at an
angle of 10 degrees. The maximum length and width was
obtained, frozen on the screen, and then measured. Re-
nal volume was calculated from methodology derived by
Dinkel [23].
GFR was measured by plasma clearance of Inutest
using a single intravenous bolus and numerical analysis
of the concentration-time curve [24]. Subjects were re-
quested to avoid dietary fructose from 17:00 hours on the
day before the test in case of interference in the assay
for Inutest (see below). On the day of the test, height
and weight of the subjects were measured, and a cannula
inserted into an antecubital vein. A basal 2 mL lithium
heparin blood sample was taken to check for endogenous
free fructose. Inutest (75 mg/kg) was injected into the vein
of the opposite arm over 2 minutes; the start of the test
was taken as the midpoint of the injection. Heparinized
blood samples (2 mL) were then taken at 5, 60, 120, 150,
and 180 minutes; the timings did not have to be exact but
were accurately recorded. Samples were centrifuged and
the plasma stored at −20◦C or −80◦C. Inutest was ana-
lyzed as fructose following preincubation of the samples
to remove free fructose and then acid hydrolysis of the
Inutest to fructose [25]. To remove free fructose, 100 lL
plasma was incubated with 50 lL of sorbitol dehydroge-
nase (SDH) and NADH (8U SDH and 10 mg NADH
per mL of 1 mol/L MOPS buffer, pH 7.2) for 1 hour at
37◦C. Theoretically and practically, up to 300 lmol/L of
fructose can be converted to sorbitol by this prein-
cubation step. To stop the reaction and precipitate
proteins, 150 lL 0.6N perchloric acid was added. To hy-
drolyze Inutest to fructose the supernatant was heated
at 70◦C for 10 minutes. The fructose was measured on
a Cobas Mira (Roche Diagnostic Systems) automated
spectrophotometer using SDH and NADH (20U SDH
and 2 mg NADH per 10 mL of 1 mol/L MOPS buffer, pH
7.2). The decline in NADH at 340 nm is proportional to
the Inutest concentration. In the basal samples the mea-
sured concentration was not significantly different from
zero (i.e., ± 10 mg/L). The GFR was calculated using
a Simplex curve-fitting procedure for the concentration-
time data, and this was then mathematically convolved
with an input function consisting of a regular series of unit
impulses to define the notional plasma response to a con-
tinuous infusion [26]. The GFR is then simply the infusion
rate divided by the plasma concentration. This approach,
unlike the simple one-compartment model convention-
ally used [27], is valid for the measurement of GFR in
normal and hyperfiltering subjects. In a proportion of sub-
jects, venous access could not be obtained in both arms
and the sampling cannula was used for injection of the In-
utest. Despite careful flushing, contamination of the early
samples could not be excluded and GFR was calculated
on the 120-, 150-, and 180-minute samples using a single
compartment model. A correction factor suitable for this
patient group (x = 0.68) was derived from the rest of the
subjects by comparing GFR results calculated by both
methods.
STATISTICAL METHODS
ACR was calculated from the geometric mean of the
3 consecutive early morning urine samples provided at
each annual assessment. Height and body mass index
(BMI, kg/m2), standard deviation score (SDS), diastolic
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and systolic blood pressure (DBPSD and SBPSD) was
calculated using age- and sex-adjusted data based on the
British 1990 growth reference charts using Coles LMS
method [28]. The latter assumes that the data can be trans-
formed to normality by a suitable power transformation
(L), and the distribution is then summarized by the me-
dian (M) and coefficient of variation (S). The values of
L, M, and S are constrained to change smoothly with
age, and the fitted values can be used to construct any re-
quired centile curves. All data were normally distributed,
except ACR, which were log transformed to allow para-
metric analyses. For each subject; clinical and biochemical
data were summarized as means and compared between
groups using an unpaired t test and association between
covariates measured with multiple regression analysis.
Prevalence rates between groups were compared using
v 2 analyses. A Kaplan Meier survival curve and log-rank
test were used to compare between groups the probabil-
ity of developing MA across age. Data at 5 and 10 years’
diabetes duration were compared using the paired t test.
To assess the proportional contribution of covariates to
risk of developing hyperfiltration and MA, a Cox model
was fitted with duration of diabetes as the time variable.
A univariate model was used to determine the relation-
ship between glomerular hyperfiltration and longitudinal
urine ACR levels. To estimate the rate of change in ACR
before 5 years’ diabetes duration for each individual, a
plot of the logarithm of median annual ACR against di-
abetes duration was represented as a linear regression
line. Thus, the annual rate of change of ACR for each
individual was estimated as the slope of the regression
line [29], and compared between groups using the Mann-
Whitney U test for independent samples. SPSS version
10.0 (Chicago, IL, USA) was used for analysis. Data are
presented as mean (SD) or median (range). A P value <
0.05 was considered significant.
RESULTS
Cohort characteristics
Characteristics of the MA−, future MA+, and MA+
groups at 5 years’ diabetes duration are described in
Table 1. For future MA+ subjects median time to onset
of MA after the initial GFR measurement was 3.3 years
(range 0.5–7.1).
Glomerular filtration in normoalbuminuric subjects
Using 5-year data from MA− subjects only (N = 243):
GFR levels correlated negatively with duration of dia-
betes (r = −0.2, P < 0.001) and positively with HbA1c
(r = 0.1, P < 0.001), but not with age, ACR, renal size,
or either systolic or diastolic BP SDS. Mean GFR lev-
els did not differ between prepubertal compared to pu-
bertal subjects (N = 46 vs. 197; 136.8 ± 34.1 vs. 134.8
± 30.4 mL/min/1.73m2, P = 0.7), or between males and
females (N = 142 vs. 101; 136.9 ± 30.2 vs. 131.8 ± 32.1
mL/min/1.73m2, P = 0.1) or between smokers and non-
smokers (N = 37 vs. 206; 135.2 ± 30.7 vs. 133.9 ± 32.7
mL/min/1.73m2, P = 0.8).
Comparison of demographic, biochemical, and clinical
data between groups at 5 years’ diabetes duration
Demographic data. In the MA+ compared to the fu-
ture MA+ and MA− groups, there was a significant trend
toward older age at assessment, but no difference existed
in the other demographic data (Table 1).
HbA1c. Mean HbA1c levels were higher in both
future MA+ subjects and MA+ subjects compared to
MA− subjects (Table 1). No difference existed between
future MA+ and MA+ subjects.
ACR. Mean ACR levels were highest in MA+ sub-
jects (Table 1). Mean ACR levels were greater in future
MA+ subjects compared to MA− subjects, although by
definition all values were within the normoalbuminuric
range.
GFR. Mean GFR levels were significantly greater in
future MA+ subjects compared to the other 2 groups. No
difference existed in mean GFR levels between MA−and
MA+ subjects (Table 1 and Fig. 2). As these results may
be confounded by duration of diabetes, if future MA+
and MA+ subjects were matched for age, sex, and du-
ration of diabetes with MA− subjects then outcome was
similar [i.e., GFR was highest in future MA+ subjects
(MA− vs. future MA+ vs. MA+; 143.3 ± 34.1 vs. 166.8
± 26.2 vs. 134.2 ± 31.8 mL/1.73m2/min, P = 0.03)].
Arterial BP. No difference existed between the groups
in systolic and diastolic BP SDS (Table 1).
Comparing subjects with and without hyperfiltration at 5
years’ diabetes duration
Using a GFR level of >125 mL/1.73m2/min as the def-
inition of hyperfiltration, at 5 years, 205 (67.8%) sub-
jects had evidence of hyperfiltration. HbA1c levels were
higher in subjects with compared to those without hyper-
filtration (10.3 ± 1.9 vs. 9.4 ± 1.8%, P < 0.001). Prevalence
of hyperfiltration was greater after compared to before
the onset of puberty (84.9 vs. 15.1%); otherwise, no other
differences existed between the groups.
To assess the proportional contribution of covariates
to risk of having hyperfiltration at 5 years’ diabetes du-
ration, a Cox model was fitted with duration of diabetes
as the time variable and hyperfiltration as the outcome
(Table 2). Risk of having hyperfiltration was associated
with poor glycemic control (i.e., a 10% increased risk for
a 1% increase in HbA1c) and with puberty (i.e., a 1.7-
fold increase with onset of puberty) and lower ACR (i.e.,
a 30% increased risk with 1 mmol/mg lower ACR). Sex,
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Table 1. Characteristics of cohort at 5 years (i.e., at time of 1st GFR), comparing normoalbuminuric subjects (MA − cases), subjects who
developed MA on subsequent follow-up (future MA+ cases), and subjects with MA at the time of assessment (MA+)
MA− Future MA+ cases MA+
Demographic data
Sample size 243 30 35
Age diagnosis of diabetes 9.1 (0.4-15.9) 9.7 (2.0-14.2) 10.6 (2.5-14.9)
Duration of diabetes 5.1 (0.1-11.1) 5.1 (3.2-6.7) 5.1 (4.8-10.8)
Age at assessment 14.1 (4.8-28.1) 14.6 (7.3-19.5) 16.3 (10.0-24.6) a,b
Birth weight kg 3.2 (0.8) 3.4 (0.8) 3.3 (0.6)
BMI SDS 0.6 (1.0) 0.8 (0.7) 0.5 (0.9)
Height SDS 0.1 (1.1) 0.1 (0.9) 0.0 (1.0)
Insulin dose U/kg 1.0 (0.3) 0.9 (0.3) 1.1 (0.3)
Clinical and biochemical data
HbA1c % 9.7 (1.8) 11.4 (1.9)c 10.8 (2.2)d
ACR mg/mmol 0.8 (0.1-5.1) 1.2 (0.4-2.7)c 3.3 (0.4-79.5)d
GFR mL/min/173m2 138.6 (30.6) 166.8 (26.2)c 134.2 (31.8)
Subjects with hyperfiltration 156 (64.2%) 29 (96.7%)e 20 (57.1%)
Renal size mL 186.3 (65.8) 254.0 (28.2) 223.8 (70.8)
BPSSD − 0.9 (1.1) − 0.7 (0.9) − 0.9 (1.1)
BPDSD 1.2 (1.1) 1.1 (1.4) 1.1 (1.2)
See statistical methods for explanation of BP SSD/DSD. Data are expressed in mean (SD) or median years (range). aP = 0.001 vs. MA − cases; b P = 0.01 vs. future
MA+ cases; cP < 0.001 vs. MA − cases; dP< 0.001 vs. MA − cases; ev 2 = 14.2, P = 0.006.
P < 0.001 P < 0.001
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Fig. 2. GFR levels in the 3 groups of subjects (MA−, future MA+,
and MA+) at 5 years’ diabetes duration (median, interquartile range).
Dashed lines represent the cutoff for the definition of hyperfiltration
(i.e., GFR >125 mL/min/173m2).
age of onset of diabetes, and blood pressure did not con-
tribute to this model.
Relationship between hyperfiltration and MA
Prevalence of hyperfiltration was greater in future
MA+ subjects compared to the other 2 groups (Table 1).
The positive predictive value of hyperfiltration for the
development of MA was 15.7% and negative predictive
value of not developing MA was 98.9% (i.e., if hyperfiltra-
tion was absent then risk for MA was minimal). The cu-
mulative probability of developing MA in the future was
Table 2. Proportional contribution (Cox model) of covariates to risk
of developing glomerular hyperfiltration with duration of diabetes as
the time variable and puberty as a time-dependent covariate
Baseline Significance Exp(B) (95% CI)
Puberty Prepuberty 0.003 1.7 (1.2-2.5)
HbA1c % 0.008 1.1 (1.0-1.2)
ACR mg/mmol 0.02 0.7 (0.5-0.9)
Covariates not contributing to model:
sex, age of diagnosis of diabetes, baseline ACR, and BP
All subjects were included in this model.
greater in subjects with hyperfiltration and high HbA1c
levels compared to subjects with no hyperfiltration and
low HbA1c levels (log rank for trend P < 0.001) (Fig. 3).
The median age of hyperfiltration was 15.1 years (range
4.8–28.1) and median age of onset of MA was 16.3 years
(7.3–24.6). From 35 MA+ subjects, 9 had persistent MA
and 26 had transient MA. In the persistent compared to
the transient MA group: mean HbA1c levels were higher
(12.1 ± 2.7 vs. 10.3 ± 1.9%, P = 0.04) yet mean GFR lev-
els were similar (132.2 ± 26.9 vs. 134.8 ± 33.8, P = 0.8) as
was prevalence of hyperfiltration (57.1% vs. 71.6%, v 2 =
1.6, P = 0.2).
Contribution of covariates to risk of developing MA
Using urine ACR as a continuous variable and com-
paring subjects with and without hyperfiltration, prior
to the first GFR measurement, no difference in median
(range) ACR levels existed [0.9 (0.1–79.5) vs. 0.8 (0.1–
27.8) mg/mmol, P = 0.9]. However, using only data from
the time of the first GFR measurement onwards, median
ACR levels were significantly greater in subjects with hy-
perfiltration [1.2 (0.1–86.4) vs. 0.9 (0.1–71.6) mg/mmol,
P = 0.003], and in a univariate model, increasing urine
ACR was related to glomerular hyperfiltration at 5 years
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Fig. 3. Cumulative probability (Kaplan-
Meier) of developing microalbuminuria
across age comparing subjects with and
without hyperfiltration (as defined by a GFR
>125 mL/min/1.73m2) and high and low
HbA1c levels.
Table 3. Proportional contribution (Cox model) of covariates to risk
of developing MA with duration of diabetes as the time variable and
puberty as a time-dependent covariate
Significance Exp(B) (95% CI)
HbA1c % 0.002 1.3 (1.1-1.5)
GFR 0.001 1.02 (1.01-1.03)
Covariates not contributing to model:
puberty, sex, age of diagnosis of diabetes, baseline ACR, and BP
Only normoalbuminuric subjects and future MA+ cases were included in this
model.
[B (95% CI) = 0.13 (0.03–0.22), P = 0.008], indepen-
dent of age [B (95% CI) = 0.03 (0.01–0.04), P < 0.001]
and HbA1c levels [B (95% CI) = 0.03 (0.01–0.04), P =
0.001]. When estimating the median rate of rise of ACR
prior to the first GFR measurement, in subjects with and
without hyperfiltration no difference existed. However
when comparing the MA− and future MA groups during
the same time period, rate of rise of ACR was greater in
the future MA group [42% per year (range −33 to169)
vs. 2% per year (range −71 to 135), P = 0.02].
To assess the proportional contribution of covariates
to risk of developing MA, a Cox model was fitted with
duration of diabetes as the time variable and MA+ in the
future as the outcome, and excluding data on subjects who
already had evidence of MA (Table 3). Risk of developing
MA was associated with poor glycemic control (i.e., a
30% increased risk for a 1% increase in HbA1c) and
higher GFR levels at baseline (i.e., a 22% increased risk
for a 10 mL/min/1.73m2 increase in GFR levels), with
other covariates not contributing to this model.
Longitudinal data (subjects with 2 GFR measurements)
One hundred and two subjects had a second GFR mea-
surement at approximately 10 years’ diabetes duration
(Fig. 1). GFR fell between 5 and 10 years’ diabetes dura-
tion (mean difference 29.7 mL/1.73m2/min, 95% CI 20.7–
38.6, P < 0.001) (i.e., a mean fall of 3.4 mL/1.73m2/min
per year) (Fig. 4). This was accompanied by a rise in urine
ACR (mean difference 3.2 mg/mmol, 95% CI 0.4–5.9,
P = 0.03), systolic BP (mean difference 6.0 mm Hg, 95%
CI 1.6–10.4, P = 0.008), and diastolic BP (mean differ-
ence 5.8 mm Hg, 95% CI 1.7–9.9, P = 0.006). Although
sample size precluded analysis of changes with respect to
albuminuria status at 5 years, the fall in GFR correlated
significantly with GFR at 5 years (r= −0.6, P < 0.001).
Relationship of renal size to microalbuminuria
Forty-two subjects from the Oxford clinic had renal
ultrasound measurements. Renal size was greater after
pubertal onset compared to prepuberty (N = 30 vs. 12,
227.7 ± 57.2 vs. 137.6 ± 32.1 mL, P < 0.001) and in subjects
with MA compared to subjects with normoalbuminuria
(N = 7 vs. 35, 247.0 ± 63.2 vs. 192.9 ± 63.0 mL, P = 0.04).
Although there was a trend toward increased renal size
in future MA+ subjects compared to MA− subjects, this
did not reach significance (Table 1). Overall renal size
correlated with ACR (r = 0.3, P = 0.02). These associa-
tions with puberty and MA were independent of glycemic
control, duration of diabetes, height, and weight SDS.
No significant associations were found with GFR and
HbA1c.
DISCUSSION
We describe longitudinal changes in annual urine albu-
min excretion and development of microalbuminuria in
relation to GFR measurements undertaken at 5 years’ di-
abetes duration in a population-based cohort of children
followed from diagnosis of T1DM. Data were censored
subsequent to any intervention therapy, making this a
true natural history study. Previous studies have been
largely cross-sectional [11, 12, 30–32] and have contained
small sample size [11, 12, 18, 19, 30, 31, 33, 34]. They re-
port data from patients with variable age and diabetes
duration at baseline and include patients on intervention
1746 Amin et al: GFR and microalbuminuria risk
160
150
140
130
120
112
110
108
106
104
74
72
70
68
66
4
3
2
1
0
P < 0.001 P = 0.03 P = 0.008 P = 0.006
5 years 10 years 5 years 10 years 5 years 10 years 5 years 10 years
G
FR
, m
L/
m
2 /m
in
M
ed
ia
n 
ur
in
e 
AC
R,
 m
g/
m
m
ol
M
ea
n 
sy
st
ol
ic 
BP
,
 
m
m
 H
g
M
ea
n 
di
as
to
lic
 B
P,
 
m
m
 H
g
Fig. 4. Data for 102 subjects who had a GFR measurement at both 5 and 10 years’ diabetes duration. Of these subjects, 72 were MA−, 20 MA+,
and 10 future MA+.
therapy [16, 19, 32, 33, 35]. Although data are conflict-
ing [18, 19], glomerular hyperfiltration has generally been
found to be predictive of MA [13, 14, 16, 17] and this ob-
servation has been confirmed in our study.
Glomerular hyperfiltration is promoted by hyper-
glycemia [36]; however, in the first studies describing an
association between hyperfiltration and the development
of microalbuminuria in T1DM, the influence of long-term
metabolic control was not accounted for [11–13]. Con-
firming findings of 3 later studies [16, 37, 38], we found
a strong relationship between risk for the development
of microalbuminuria between 5 and 10 years’ diabetes
duration and glomerular hyperfiltration at 5 years’ dia-
betes duration, independent of glycemic control. Further-
more, median urine ACR levels were similar prior to the
first GFR measurement, but after this time, increasing
urine ACR levels were related to glomerular hyperfil-
tration, independent of HbA1c levels. Of the previous 3
studies, 1 had small sample size and variable duration of
diabetes [37], another was cross-sectional and involved
adults of long diabetes duration [38]. The third study, by
Rudberg et al, was a larger, prospective but clinic-based
study following 64 subjects for 8 years [16]. Subjects were
young but not followed from diagnosis of diabetes and
had poor metabolic control at baseline. In addition, no
relationship was found between microalbuminuria and
glycemic control, possibly because early measurements
of HbA1c were unavailable. In the present study, the risk
for microalbuminuria in the absence of hyperfiltration
was minimal even in the presence of high HbA1c levels
(Fig. 3). These data are consistent with Rudberg’s find-
ings [16] and suggest hyperfiltration is a prerequisite for
nephropathy. Thus, for young subjects of short diabetes
duration, we confirm that glomerular hyperfiltration is
strongly predictive of the development of microalbumin-
uria, independent of glycemic control, and is not preceded
by raised urine ACR levels. However, the stimuli provok-
ing such changes in the early diabetic kidney are unclear.
We found puberty to be a risk factor for hyperfiltra-
tion, suggesting that these changes may relate to pubertal
hormonal changes. The tubular hypothesis of glomerular
filtration suggests that the effect of diabetes on glomeru-
lar filtration may stem from primary effects on the
proximal tubule impacting on glomerular filtration, by
tubuloglomerular feedback via the macula densa. Evi-
dence exists in diabetic rats [39] and humans [40] for
a primary increase in proximal tubular reabsorption,
resulting in reduced macula densa sodium chloride con-
centration and finally glomerular hyperfiltration. Com-
pelling evidence suggests the cause of such changes may
involve hormonal factors acting at the proximal tubule,
increasing tubular growth. Proximal tubular growth ac-
counts for most of the increased kidney mass seen in early
diabetes, and experimental blocking of ornithine decar-
boxylase, the rate-limiting step in tubular growth, results
in attenuated kidney growth and reduction in GFR [39].
These changes may relate to abnormalities of the
growth hormone (GH) axis because GH levels are in-
creased in T1DM, particularly during puberty [41]. Renal
growth is in part dependent on GH [42] and diabetic rat
models show evidence of high renal cortical GH binding
protein mRNA levels and high paracrine IGF-I gener-
ation in association with nephromegaly, glomerular hy-
perfiltration [42], and glomerulosclerosis similar to that
seen in human diabetic kidney [43], with reversal of these
changes with GH blockade [44]. In keeping with these ex-
perimental data, clinical studies in early diabetes showed
an association between increased kidney size and GFR
[11, 12] and this is predictive of nephropathy [13, 14].
In the present study, kidney size correlated with urine
albumin excretion and was greatest in the future MA+
group, although this did not reach statistical significance.
Furthermore, our group has previously found MA risk to
be related to lower circulating IGF-I levels [45] and due
to lack of negative feedback drive, higher GH levels [46].
Our data indicate that arterial BP was not predictive
of microalbuminuria, but analysis of limited follow-up
data at 10 years suggests increasing albumin excretion
and BP rise are associated with a decline in GFR. This
is consistent with previous reported data from the same
(ORPS) cohort [47], and from clinical and morphologic
data from Rudberg et al [16, 31]. These data suggest
that while increased BP may be associated with acceler-
ated renal damage, it is not responsible for its initiation.
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Antihypertensive medication lessens renal injury; how-
ever, amelioration of glomerular hypertension may be
more critical. In experimental studies, treating systemic
hypertension while maintaining abnormal glomerular
pressure and flow does not protect against renal injury,
whereas normalization of glomerular pressure protects
against progression to proteinuria, despite persistence of
hyperfiltration [3, 4] or hyperglycemia [10]. Angiotensin-
converting enzyme inhibitors (ACEI) and angiotensin re-
ceptor blockers (ARB) are highly effective in reducing
glomerular hypertension in a variety of rodent models of
renal injury [48], and this may explain their efficacy in
preventing progression of microalbuminuria.
Randomized trials of captopril [49] and ARBs [50, 51]
reduce urine albumin excretion, diabetic nephropathy
risk, development of end-stage renal disease, need for
dialysis, and death. Our data demonstrating the tempo-
ral relationship between hyperfiltration and microalbu-
minuria risk suggest that such medication may induce
beneficial glomerular hemodynamic changes in poorly
controlled pubertal T1DM subjects who hyperfiltrate ir-
respective of albuminuric status. Further support of this
hypothesis stems from the increased rate of rise of ACR
prior to the onset of microalbuminuria in future MA
subjects in the early years of diabetes, which previous
data from our group have found to be predictive of
microalbuminuria [29].
In up to 50% of subjects microalbuminuria regresses
[20]; however, we found that GFR levels and preva-
lence of hyperfiltration were similar in subjects with tran-
sient compared to persistent MA subjects, despite lower
HbA1c levels in the transient group. This suggests that
the transient microalbuminuric group may be protected
from progression by better glycemic control, but may be-
come persistent in later life. Glomerular hyperfiltration,
progression of renal injury, and the response to medi-
cation may also be dependent on genotype, as microal-
buminuric subjects with the D-allele of the ACE gene
demonstrate increased morphologic progression of
nephropathy, which is limited by ACE inhibition [52].
Follow-up data in the current study were limited
and the associations between GFR, blood pressure,
urine ACR, and persistence of MA must be interpreted
with caution until further long-term follow-up data are
available.
CONCLUSION
We have demonstrated the impact of glomerular hy-
perfiltration on increasing urine albumin excretion, and
the development of microalbuminuria in children and
adolescents followed from diagnosis of T1DM. Our data
indicate that hyperfiltration may relate to factors other
than poor glycemic control, such as hormonal abnor-
malities occurring in predisposed individuals during pu-
berty, but further physiologic studies are required to ver-
ify these associations. Blood pressure appears to play no
role in the initiation of renal injury, but our findings sug-
gest that intervention to reduce GFR may benefit poorly
controlled pubertal subjects who hyperfiltrate, even be-
fore the onset of microalbuminuria. However, confir-
mation of this hypothesis would require randomized,
controlled trials.
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